In 2023, the treatment success rate for patients with extensively drug-resistant tuberculosis in Canada stood at 64%. The forecast for 2024 to 2028 indicates a gradual decline in success rates, dropping from 62% in 2024 to 56% in 2028. Year-on-year variations suggest a consistent decrease, with an average annual decline of around 2% over the forecast period. The compound annual growth rate (CAGR) for these years reflects a negative trend.
Future trends to watch for include:
- The impact of new treatment protocols and drug developments on success rates.
- Potential shifts in healthcare funding and resource allocation affecting treatment efficacy.
- The role of public health initiatives and preventive measures in managing the disease.
